TCE ACC Postgraduate Scholarship in Novel Noncoding RNA-Based Therapy for Adrenocortical Cancer

A unique scholarship opportunity is available for an outstanding Research Masters of PhD scholar to conduct research into novel noncoding RNA-based therapy for adrenocortical cancer.

Scholarship value and duration
The Scholarship will provide a stipend allowance of $20,000 per annum for up to one year, subject to satisfactory academic performance.

An extension may be offered by the University should funds become available and subject to passing the annual progress review.

The maximum duration of the scholarship (including any extension) will not exceed three years for a PhD student, or two years for a Research Masters student.

Eligibility criteria
1. This scholarship is offered subject to the applicant having an unconditional offer of admission or being currently enrolled in full-time studies in a Research Masters or PhD within the Sydney Medical School at the University of Sydney.

2. Applicants must have previous experience in surgical procedures.

3. Applicants must hold a recognised medical degree in a related discipline.

For more information
Student Administration Services
T 1800 SYD UNI (1800 793 864)
T +61 2 8627 1444 (outside Australia)
E scholarships.officer@sydney.edu.au

Background
A unique scholarship opportunity is available for an outstanding Research Masters of PhD scholar to conduct research into novel noncoding RNA-based therapy for adrenocortical cancer.

The scholarship is provided by Sydney Vital through a Cancer Institute NSW Grant.

Selection criteria
The successful applicant will be awarded the scholarship on the basis of:

− Academic merit,
− Previous research experience, and
− Research potential in the areas of translational endocrine cancer research.

The successful applicant will be selected on the nomination of Associate Professor Dr Jing Zhao or nominee.

Payment schedule
− Fortnightly stipend payments.
TCE ACC Postgraduate Scholarship in Novel Noncoding RNA-Based Therapy for Adrenocortical Cancer
Terms and Conditions
August 2017

1. Background
   a. A unique scholarship opportunity is available for an outstanding Research Masters or PhD scholar to conduct research into novel noncoding RNA-based therapy for adrenocortical cancer.

   b. The scholarship is provided by Sydney Vital through a Cancer Institute NSW Grant.

2. Eligibility
   a. This scholarship is offered subject to the applicant having an unconditional offer of admission or being currently enrolled in full-time studies in a Research Masters or PhD within the Sydney Medical School at the University of Sydney.

   b. Applicants must have previous experience in surgical procedures.

   c. Applicants must hold a recognised medical degree in a related discipline.

3. Selection Criteria
   a. The successful applicant will be awarded the Scholarship on the basis of:

      I. academic merit,
      II. previous research experience, and
      III. research potential in the areas of translational endocrine cancer research.

   b. The successful applicant will be awarded the Scholarship by the nomination of Dr Jing Zhao or nominee.

4. Value
   a. The Scholarship will provide a stipend allowance of $20,000 per annum for up to one year, subject to satisfactory academic performance.

   b. An extension may be offered by the University should funds become available and subject to passing the annual progress review.

   c. The maximum duration of the scholarship (including any extension) will not exceed three years for a PhD student, or two years for a Research Masters student.

   d. Academic course fees and the Student Services Amenities fee are not provided for a successful international applicant.

   e. Periods of study already undertaken towards the degree prior to the commencement of the Scholarship, will be deducted from the maximum duration of the Scholarship excluding the potential extension period.
TCE ACC Postgraduate Scholarship in Novel Noncoding RNA-Based Therapy for Adrenocortical Cancer

f. The Scholarship is for commencement in 2017 or 2018 and cannot be deferred or transferred to another area of research.

g. No other amount is payable.

h. The Scholarship will be offered subject to the availability of funding.

5. Eligibility for Progression

a. Progression is subject to passing the annual progress review.

6. Leave Arrangements

a. The Scholarship recipient receives up to 20 working days recreation leave each year of the Scholarship and this may be accrued. However, the student will forfeit any unused leave remaining when the Scholarship is terminated or complete. Recreation leave does not attract a leave loading and the supervisor’s agreement must be obtained before leave is taken.

b. The Scholarship recipient may take up to 10 working days sick leave each year of the Scholarship and this may be accrued over the tenure of the Scholarship. Students with family responsibilities, caring for sick children or relatives, or experiencing domestic violence, may convert up to five days of their annual sick leave entitlement to carers leave on presentation of medical certificate(s). Students taking sick leave must inform their supervisor as soon as practicable.

7. Research Overseas

a. The Scholarship recipient may not normally conduct research overseas within the first six months of award.

b. The Scholarship holder may conduct up to 12 months of their research outside Australia. Approval must be sought from the student’s supervisor, Head of Department and HDRAC, and will only be granted if the research is essential for completion of the degree. All periods of overseas research are cumulative and will be counted towards a student’s candidature. Students must remain enrolled full-time at the University and receive approval to count time away.

8. Suspension

a. The Scholarship recipient cannot suspend their award.

9. Changes in Enrolment

a. The Scholarship recipient must notify HDRAC and their supervisor promptly of any planned changes to their enrolment including but not limited to: attendance pattern, suspension, leave of absence, withdrawal, course transfer, and candidature upgrade or downgrade. If the award holder does not provide notice of the changes identified above, the University may require repayment of any overpaid stipend.

10. Termination
11. Misconduct

a. Where during the Scholarship a student engages in misconduct, or other inappropriate conduct (either during the Scholarship or in connection with the student’s application and eligibility for the Scholarship), which in the opinion of the University warrants recovery of funds paid to the student, the University may require the student to repay stipend amounts and any other payments made to the student in connection with the Scholarship. Examples of such conduct include and without limitation; academic dishonesty, research misconduct within the meaning of the Research Code of Conduct (for example, plagiarism in proposing, carrying out or reporting the results of research, or failure to declare or manage a serious conflict of interests), breach of the Code of Conduct for Students and misrepresentation in the application materials or other documentation associated with the Scholarship.

b. The University may require such repayment at any time during or after the Scholarship period. In addition, by accepting this Scholarship, the student consents to all aspects of
TCE ACC Postgraduate Scholarship in Novel Noncoding RNA-Based Therapy for Adrenocortical Cancer

any investigation into misconduct in connection with this Scholarship being disclosed by the University to the funding body and/or any relevant professional body.

12. Acknowledgement

a. if the student does not acknowledge Sydney Vital on all publications and research outputs associated with the scholarship by using the below paragraph:

This project was supported by Sydney Vital, Translational Cancer Research, through a Cancer Institute NSW competitive grant. The views expressed herein are those of the authors and are not necessarily those of the Cancer Institute NSW.